Long-term use and risk of major adverse cardiac events: Comparing enzalutamide and abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer.
Chen HK, Su PJ, Wang YL, Chang KC, Su YL, Chang PH, Kuan FC, Hsieh CH, Kuo YC, Sheng TW, Chang CF, Yu SM, Huang WK, Lin YC, Tsan DL, Yu KJ, Lin PH, Chen HY, Chang YH, Pang ST, Chuang CK, Lai EC.
Chen HK, et al. Among authors: lin ph.
Int J Cancer. 2023 Mar 15;152(6):1191-1201. doi: 10.1002/ijc.34348. Epub 2022 Dec 9.
Int J Cancer. 2023.
PMID: 36346116
Free article.
This is a retrospective cohort study by analyzing a multi-institutional electronic medical records database in Taiwan to compare long-term effectiveness and risk of major adverse cardiac events (MACE) in chemotherapy-naive metastatic castration-resistant prostate cancer (m …
This is a retrospective cohort study by analyzing a multi-institutional electronic medical records database in Taiwan to compare long-ter …